Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol
- PMID: 53656
- DOI: 10.1016/s0140-6736(75)92656-2
Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol
Abstract
Seven patients with osteoporosis of ageing were treated with synthetic 1alpha-hydroxycholecalciferol (1alpha-H.C.C.) for 3-4 months. The compound was given at a daily oral dose of 2 mug together with an oral supplement of 1 g of calcium. Clinically there was a striking improvement in the patients' physical fitness. Increased bone formation and mineralisation were seen on iliac-crest bone biopsy, and this was supported by an increased osteoblastic activity demonstrated by histochemical measurement of alkaline-phosphatase activity. Bone histology furthermore showed a reduced bone resorption, which was supported by a reduced urinary excretion of total hydroxyproline. Photon absorptiometry of the forearm accorded with the histological findings, showing a significant increase in the bone mineral content. Serum-calcium rose in all patients, one developing a severe transitory hypercalcaemia. The urinary excretion of calcium and magnesium increased significantly. The serum concentrations of 25-hydroxycholecalciferol and parathyroid hormone were not significantly affected by the treatment. It is concluded that 1alpha-H.C.C. is an effective tool in the treatment of senile osteoporosis.
Similar articles
-
Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment.Isr J Med Sci. 1977 Mar;13(3):253-8. Isr J Med Sci. 1977. PMID: 852974
-
Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.Lancet. 1976 May 15;1(7968):1044-7. doi: 10.1016/s0140-6736(76)92220-0. Lancet. 1976. PMID: 57451 Clinical Trial.
-
1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.Nephron. 1976;16(5):359-70. doi: 10.1159/000180662. Nephron. 1976. PMID: 1264309
-
Ageing of bone: its relation to osteoporosis and osteoarthrosis in post-menopausal women.Front Horm Res. 1975;3:116-30. doi: 10.1159/000398271. Front Horm Res. 1975. PMID: 791695 Review. No abstract available.
-
Can biochemical markers tell us anything about rate of bone loss?Scand J Clin Lab Invest Suppl. 1994;219:40-1. doi: 10.3109/00365519409088576. Scand J Clin Lab Invest Suppl. 1994. PMID: 7701239 Review. No abstract available.
Cited by
-
Bone disease in the elderly.Proc R Soc Med. 1976 Dec;69(12):925-6. doi: 10.1177/003591577606901215. Proc R Soc Med. 1976. PMID: 1013134 Free PMC article. No abstract available.
-
25-Hydroxycholecalciferol in experimental osteoporosis.Clin Rheumatol. 1985 Sep;4(3):290-3. doi: 10.1007/BF02031610. Clin Rheumatol. 1985. PMID: 4064586
-
Vitamin D metabolism and the response to 1,25-dihydroxycholecalciferol in osteoporosis.Calcif Tissue Res. 1977 May;22 Suppl:74-7. doi: 10.1007/BF02064044. Calcif Tissue Res. 1977. PMID: 199338 No abstract available.
-
Serum vitamin D metabolites in younger and elderly postmenopausal women.Calcif Tissue Int. 1984 Jan;36(1):19-24. doi: 10.1007/BF02405289. Calcif Tissue Int. 1984. PMID: 6423232
-
Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.Br Med J. 1976 Jul 10;2(6027):79-83. doi: 10.1136/bmj.2.6027.79. Br Med J. 1976. PMID: 1276820 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources